Disrupting tumour blood vessels (original) (raw)

• Boyland, E. & Boyland, M. E. Studies in tissue metabolism. IX. The action of colchicine and B. typhosus extract. Biochem. J. 31, 454–460 (1937).
  CAS PubMed PubMed Central Google Scholar
• Seed, L., Slaughter, D. P. & Limarzi, L. R. Effect of colchicine on human carcinoma. Surgery 7, 696–709 (1940).
  Google Scholar
• Ludford, R. J. Factors determining the action of colchicine on tumour growth. Br. J. Cancer 2, 75–86 (1948).
  CAS PubMed PubMed Central Google Scholar
• Algire, G. H., Legallais, F. Y. & Anderson, B. F. Vascular reactions of normal and malignant tissues in vivo. VI. The role of hypotension in the action of components of podophyllotoxin on transplanted sarcomas. J. Natl Cancer Inst. 14, 879–887 (1954). One of a classic series of papers on the vascular reactions of tumours.
  CAS PubMed Google Scholar
• Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L. & Zwi, L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer 27, 482–487 (1991).
  CAS PubMed Google Scholar
• Hill, S. A., Lonergan, S. J., Denekamp, J. & Chaplin, D. J. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur. J. Cancer 9, 1320–1324 (1993).
  Google Scholar
• Hill, S. A., Sampson, L. E. & Chaplin, D. J. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int. J. Cancer 63, 119–123 (1995).
  CAS PubMed Google Scholar
• Pettit, G. R., Cragg, G. M. & Singh, S. B. Antineoplastic agents, 122. Constituents of Combretum caffrum. J. Nat. Prod. 50, 386–391 (1987). Describes the isolation of the combretastatins from their natural source.
  CAS PubMed Google Scholar
• Lin, C. M. et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structural-activity study. Mol. Pharmacol. 34, 200–208 (1988).
  CAS PubMed Google Scholar
• Pettit, G. R. et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 10, 299–309 (1995). Describes the synthesis of CA-4-P, the more soluble prodrug of CA-4, allowing its use in in vivo model systems.
  CAS PubMed Google Scholar
• McGown, A. T. & Fox, B. W. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des. 3, 249–254 (1989).
  PubMed Google Scholar
• Pettit, G. R. & Lippert III, J. W. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des. 15, 203–216 (2000).
  CAS PubMed Google Scholar
• Holwell, S. E. & Bibby, M. C. Activity of combretastatin A1 phosphate in murine models of liver metastasis. Br. J. Cancer 85 (Suppl. 1), 34 (2001).
  Google Scholar
• Hill, S. A., Tozer, G. M. & Chaplin, D. J. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res. 22, 1453–1458 (2002).
  CAS PubMed Google Scholar
• Holwell, S. E. et al. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo vascular effects in experimental tumours. Anticancer Res. 22, 707–711 (2002).
  CAS PubMed Google Scholar
• Hua, J. et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 23, 1433–1440 (2003).
  CAS PubMed Google Scholar
• Aleksandrzak, K., McGown, A. T. & Hadfield, J. A. Antimitotic activity of diaryl compounds with structures resembling combretastatin A-4. Anticancer Drugs 9, 545–550 (1998).
  CAS PubMed Google Scholar
• Hatanaka, T. et al. Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg. Med. Chem. Lett. 8, 3371–3374 (1998).
  CAS PubMed Google Scholar
• Ohsumi, K. et al. Novel combretastatin analogues effective against murine solid tumors: design and structure–activity relationships. J. Med. Chem. 41, 3022–3032 (1998).
  CAS PubMed Google Scholar
• Pettit, G. R. et al. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J. Med. Chem. 41, 1688–1695 (1998).
  CAS PubMed Google Scholar
• Lawrence, N. J., Rennison, D., Woo, M., McGown, A. T. & Hadfield, J. A. Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg. Med. Chem. Lett. 11, 51–54 (2001).
  CAS PubMed Google Scholar
• Hadimani, M. B. et al. Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. Bioorg. Med. Chem. Lett. 13, 1505–1508 (2003).
  CAS PubMed Google Scholar
• Liou, J. P. et al. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J. Med. Chem. 47, 4247–4257 (2004).
  CAS PubMed Google Scholar
• Perez-Melero, C. et al. A new family of quinoline and quinoxaline analogues of combretastatins. Bioorg. Med. Chem. Lett. 14, 3771–3774 (2004).
  CAS PubMed Google Scholar
• Sun, L., Vasilevich, N. I., Fuselier, J. A., Hocart, S. J. & Coy, D. H. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg. Med. Chem. Lett. 14, 2041–2046 (2004).
  CAS PubMed Google Scholar
• Prinz, H. Recent advances in the field of tubulin polymerization inhibitors. Expert Rev. Anticancer Ther. 2, 695–708 (2002).
  CAS PubMed Google Scholar
• Hori, K., Saito, S., Nihei, Y., Suzuki, M. & Sato, Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn. J. Cancer Res. 90, 1026–1038 (1999).
  CAS PubMed PubMed Central Google Scholar
• Nihei, Y. et al. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn. J. Cancer Res. 90, 1016–1025 (1999).
  CAS PubMed PubMed Central Google Scholar
• Hori, K., Saito, S., Sato, Y. & Kubota, K. Stoppage of blood flow in 3-methylcholanthrene-induced primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med. Sci. Monit. 7, 26–33 (2001).
  CAS PubMed Google Scholar
• Hori, K., Saito, S. & Kubota, K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br. J. Cancer 86, 1604–1614 (2002).
  CAS PubMed PubMed Central Google Scholar
• Beauregard, D. A. et al. Magnetic resonance imaging and spectroscopy of combretastain A4 prodrug-induced disruption of tumour perfusion and energetic status. Br. J. Cancer 77, 1761–1767 (1998).
  CAS PubMed PubMed Central Google Scholar
• Dark, G. D. et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57, 1829–1834 (1997). The first solid evidence for the combretastatins having a potent and selective vascular-disrupting effect in solid tumours.
  CAS PubMed Google Scholar
• Horsman, M., Ehrnrooth, E., Ladekarl, M. & Overgaard, J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int. J. Radiat. Oncol. Biol. Phys. 42, 895–898 (1998).
  CAS PubMed Google Scholar
• Maxwell, R. J., Nielsen, F. U., Breidahl, T., Stodkilde-Jorgensen, H. & Horsman, M. R. Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI. Int. J. Radiat. Oncol. Biol. Phys. 42, 891–894 (1998).
  CAS PubMed Google Scholar
• Chaplin, D. J., Pettit, G. R. & Hill, S. A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 19, 189–196 (1999).
  CAS PubMed Google Scholar
• Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R. & Bibby, M. C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 81, 1318–1327 (1999).
  CAS PubMed PubMed Central Google Scholar
• Tozer, G. M. et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 59, 1626–1634 (1999).
  CAS PubMed Google Scholar
• Pedley, R. B. et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-_O_-phosphate. Cancer Res. 61, 4716–4722 (2001).
  CAS PubMed Google Scholar
• Lin, C. M., Ho, H. H., Pettit, G. R. & Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 28, 6984–6991 (1989).
  CAS PubMed Google Scholar
• Rustin, G. J. et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 21, 2815–2822 (2003).
  CAS PubMed Google Scholar
• Plowman, J. et al. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat. Rep. 70, 631–635 (1986).
  CAS PubMed Google Scholar
• Smith, G. P., Calveley, S. B., Smith, M. J. & Baguley, B. C. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur. J. Cancer Clin. Oncol. 23, 1209–1211 (1987).
  CAS PubMed Google Scholar
• Evelhoch, J. L. et al. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 48, 4749–4755 (1988).
  CAS PubMed Google Scholar
• Hill, S. A., Williams, K. B. & Denekamp, J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur. J. Cancer Clin. Oncol. 25, 1419–1424 (1989).
  CAS PubMed Google Scholar
• Zwi, L. J., Baguley, B. C., Gavin, J. B. & Wilson, W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J. Natl. Cancer Inst. 81, 1005–1013 (1989). References 44 and 45 provide an early introduction to the concept of vascular shutdown and how it might be measured.
  CAS PubMed Google Scholar
• Denekamp, J., Hill, S. A. & Hobson, B. Vascular occlusion and tumour cell death. Eur. J. Cancer Clin. Oncl. 19, 271–275 (1983).
  CAS Google Scholar
• Baguley, B. C. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 4, 141–148 (2003).
  CAS PubMed Google Scholar
• Jameson, M. B. et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br. J. Cancer 88, 1844–1850 (2003). Report of the clinical trial of DMXAA that discusses some of the issues that have to be addressed when measuring tumour vascular effects in the clinic.
  CAS PubMed PubMed Central Google Scholar
• Tozer, G. M. et al. Mechanisms associated with tumor vascular shutdown induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61, 6413–6422 (2001). Detailed study of mechanisms of action of CA-4–P at the physiological level.
  CAS PubMed Google Scholar
• Zwi, L. J., Baguley, B. C., Gavin, J. B. & Wilson, W. R. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol. Res. 6, 79–85 (1994).
  CAS PubMed Google Scholar
• Galbraith, S. M. et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21, 93–102 (2001).
  CAS PubMed Google Scholar
• Kanthou, C. & Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060–2069 (2002). Study of the cell-signalling events in endothelial cells in vitro , which are initiated by the effects of CA-4-P on the tubulin cytoskeleton and lead to functional changes in terms of monolayer permeability and assembly of junctional proteins.
  CAS PubMed Google Scholar
• Tozer, G. M., Kanthou, C., Parkins, C. S. & Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 83, 21–38 (2002).
  CAS PubMed PubMed Central Google Scholar
• Tozer, G. M. et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv. Drug Deliv. Rev. 57, 135–152 (2005).
  CAS PubMed Google Scholar
• Zhao, L., Ching, L. M., Kestell, P., Kelland, L. R. & Baguley, B. C. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4–acetic acid (DMXAA): Increased tumor vascular permeability. Int. J. Cancer (in the press).
• Milosevic, M. F., Fyles, A. W. & Hill, R. P. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int. J. Radiat. Oncol. Biol. Phys. 43, 1111–1123 (1999). An instructive analysis of the role of interstitial fluid pressure in the control of tumour blood flow.
  CAS PubMed Google Scholar
• Blakey, D. C. et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 8, 1974–1983 (2002).
  CAS PubMed Google Scholar
• Hori, K. & Saito, S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br. J. Cancer 89, 1334–1344 (2003).
  CAS PubMed PubMed Central Google Scholar
• Hori, K. & Saito, S. Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700). Br. J. Cancer 90, 549–553 (2004).
  CAS PubMed PubMed Central Google Scholar
• Less, J. R., Skalak, T. C., Sevick, E. M. & Jain, R. K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res. 51, 265–273 (1991).
  CAS PubMed Google Scholar
• Lominadze, D. & Mchedlishvili, G. Red blood cell behavior at low flow rate in microvessels. Microvasc. Res. 58, 187–189 (1999).
  CAS PubMed Google Scholar
• Dudek, S. M. & Garcia, J. G. Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 91, 1487–1500 (2001).
  CAS PubMed Google Scholar
• Dejana, E., Spagnuolo, R. & Bazzoni, G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb. Haemost. 86, 308–315 (2001).
  CAS PubMed Google Scholar
• Dvorak, H. F., Nagy, J. A., Dvorak, J. T. & Dvorak, A. M. Identification and characerization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95–109 (1988).
  CAS PubMed PubMed Central Google Scholar
• Lum, H. & Malik, A. B. Mechanisms of increased endothelial permeability. Can. J. Physiol. Pharmacol. 74, 787–800 (1996).
  CAS PubMed Google Scholar
• Bates, D. O. & Harper, S. J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul. Pharmacol. 39, 225–237 (2002).
  CAS PubMed Google Scholar
• Su, M. Y. et al. Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI. Magn. Reson. Med. 36, 868–877 (1996).
  CAS PubMed Google Scholar
• Johansson, M., Henriksson, R., Bergenheim, A. T. & Koskinen, L. O. Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma. Br. J. Cancer 83, 826–832 (2000).
  CAS PubMed PubMed Central Google Scholar
• Wojciak-Stothard, B. & Ridley, A. J. Rho GTPases and the regulation of endothelial permeability. Vascul. Pharmacol. 39, 187–199 (2002).
  CAS PubMed Google Scholar
• Garcia, J. G., Davis, H. W. & Patterson, C. E. Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J. Cell Physiol. 163, 510–522 (1995).
  CAS PubMed Google Scholar
• Amano, M. et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 271, 20246–20249 (1996).
  CAS PubMed Google Scholar
• Verin, A. D. et al. Microtubule disassembly increases endothelial cell barrier dysfunction: role of MLC phosphorylation. Am. J. Physiol. Lung Cell Mol. Physiol. 281, L565–L574 (2001).
  CAS PubMed Google Scholar
• Ye, L. H. et al. Myosin light-chain kinase of smooth muscle stimulates myosin ATPase activity without phosphorylating myosin light chain. Proc. Natl Acad. Sci. USA 96, 6666–6671 (1999).
  CAS PubMed PubMed Central Google Scholar
• Brooks, A. C. et al. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. Anticancer Res. 23, 3199–3206 (2003).
  CAS PubMed Google Scholar
• Parkins, C. S., Holder, A. J., Hill, S. A., Chaplin, D. J. & Tozer, G. M. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br. J. Cancer 83, 811–816 (2000).
  CAS PubMed PubMed Central Google Scholar
• Korbelik, M. & Cecic, I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 137, 91–98 (1999).
  CAS PubMed Google Scholar
• Prise, V. E., Honess, D. J., Stratford, M. R. L., Wilson, J. & Tozer, G. M. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 21, 717–726 (2002).
  CAS PubMed Google Scholar
• Nihei, Y. et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn. J. Cancer Res. 90, 1387–1396 (1999).
  CAS PubMed PubMed Central Google Scholar
• Baguley, B. C., Zhuang, L. & Kestell, P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol. Res. 9, 55–60 (1997).
  CAS PubMed Google Scholar
• Alexander, J. S., Hechtman, H. B. & Shepro, D. Serotonin induced actin polymerization and association with cytoskeletal elements in cultured bovine aortic endothelium. Biochem. Biophys. Res. Commun. 143, 152–158 (1987).
  CAS PubMed Google Scholar
• Lash, C. J. et al. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer 78, 439–445 (1998).
  CAS PubMed PubMed Central Google Scholar
• Ahmed, B. et al. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int. J. Cancer 105, 20–25 (2003).
  CAS PubMed Google Scholar
• Iyer, S. et al. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58, 4510–4514 (1998).
  CAS PubMed Google Scholar
• Kanthou, C. et al. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am. J. Pathol. 165, 1401–1411 (2004).
  CAS PubMed PubMed Central Google Scholar
• Hill, S. A., Chaplin, D. J., Lewis, G. & Tozer, G. M. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int. J. Cancer 102, 70–74 (2002).
  CAS PubMed Google Scholar
• Ching, L. M. et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br. J. Cancer 86, 1937–1942 (2002).
  CAS PubMed PubMed Central Google Scholar
• Sheng, Y. et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int. J. Cancer 111, 604–610 (2004).
  CAS PubMed Google Scholar
• Kirwan, I. G. et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin. Cancer Res. 10, 1446–1453 (2004).
  CAS PubMed Google Scholar
• Cao, Z., Baguley, B. C. & Ching, L. M. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 61, 1517–1521 (2001).
  CAS PubMed Google Scholar
• Zhao, L., Ching, L. M., Kestell, P. & Baguley, B. C. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clin. Cancer Res. 9, 6545–6550 (2003).
  CAS PubMed Google Scholar
• Hendrix, M. J. et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl Acad. Sci. USA 98, 8018–8023 (2001).
  CAS PubMed PubMed Central Google Scholar
• Zhao, L. S., Edgar, E., Marshall, L., Kelland, L. & Baguley, B. C. Inhibition of vasculogenic mimicry in melanoma by the antivascular drug 5,6-dimethylxanthenone-4–acetic acid (DMXAA). Eur. J. Cancer Suppl. 2 (8), 47 (2004).
  Google Scholar
• Ching, L. M. et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 59, 3304–3307 (1999). Gives an introduction to the role of cytokines in the action of DMXAA.
  CAS PubMed Google Scholar
• Wang, L. C. et al. Induction of tumour necrosis factor and interferon-g in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem. Pharmacol. 67, 937–945 (2004).
  CAS PubMed Google Scholar
• Kallinowski, F., Schaefer, C., Tyler, G. & Vaupel, P. In vivo targets of recombinant human tumour necrosis factor-α: blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br. J. Cancer 60, 555–560 (1989).
  CAS PubMed PubMed Central Google Scholar
• Murata, R., Overgaard, J. & Horsman, M. R. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int. J. Radiat. Biol. 77, 195–204 (2001).
  CAS PubMed Google Scholar
• Denekamp, J. & Hobson, B. Endothelial cell proliferation in experimental tumours. Br. J. Cancer 46, 711–720 (1982). One of a series of papers by this author setting out the principles and potential for therapeutic targeting of the tumour vasculature, which was influential in stimulating research in this field.
  CAS PubMed PubMed Central Google Scholar
• Eberhard, A. et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60, 1388–1393 (2000).
  CAS PubMed Google Scholar
• Park, J. H. et al. Hypoxia/aglycemia increases endothelial permeability: role of second messengers and cytoskeleton. Am. J. Physiol. 277, C1066–C1074 (1999).
  CAS PubMed Google Scholar
• Paria, B. C. et al. Tumor necrosis factor-alpha-induced TRPC1 expression amplifies store-operated Ca2+ influx and endothelial permeability. Am. J. Physiol. Lung Cell Mol. Physiol. 287, L1303–L1313 (2004).
  CAS PubMed Google Scholar
• Michel, C. C. & Curry, F. E. Microvascular permeability. Physiol. Rev. 79, 703–761 (1999). An excellent comprehensive review of microvascular permeability from the molecular to the physiological level.
  CAS PubMed Google Scholar
• Tiruppathi, C., Minshall, R. D., Paria, B. C., Vogel, S. M. & Malik, A. B. Role of Ca2+ signaling in the regulation of endothelial permeability. Vascul. Pharmacol. 39, 173–185 (2002).
  CAS PubMed Google Scholar
• Beauregard, D. A., Hill, S. A., Chaplin, D. J. & Brindle, K. M. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res. 61, 6811–6815. (2001).
  CAS PubMed Google Scholar
• Otani, M. et al. TZT-1027, an antimicrotubule agent attacks tumor vasculature and induces tumor cell death. Japn. J. Cancer Res. 91, 837–844 (2000).
  CAS Google Scholar
• Lew, Y. S., Brown, S. L., Griffin, R. J., Song, C. W. & Kim, J. H. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res. 59, 6033–6037 (1999).
  CAS PubMed Google Scholar
• Davis, P. D. et al. ZD6126: a novel vascular-targeting agent that causes destruction of tumor vasculature. Cancer Res. 62, 7247–7253 (2002).
  CAS PubMed Google Scholar
• Segreti, J. A. et al. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother. Pharmacol. 54, 273–281 (2004).
  CAS PubMed Google Scholar
• Kasibhatla, S. et al. Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Mol. Cancer Ther. 3, 1365–1374 (2004).
  CAS PubMed Google Scholar
• Corada, M. et al. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100, 905–911 (2002).
  CAS PubMed Google Scholar
• Blaschuk, O. W. & Rowlands, T. M. Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metastasis Rev. 19, 1–5 (2000).
  CAS PubMed Google Scholar
• Abramovitch, R., Dafni, H., Smouha, E., Benjamin, L. E. & Neeman, M. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res. 59, 5012–5016 (1999).
  CAS PubMed Google Scholar
• Ashrafpour, H. et al. Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature. Am. J. Physiol. Heart. Circ. Physiol. 286, H946–H954 (2004).
  CAS PubMed Google Scholar
• Inai, T. et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165, 35–52 (2004).
  CAS PubMed PubMed Central Google Scholar
• Thorpe, P. E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10, 415–427 (2004).
  PubMed Google Scholar
• Dowlati, A. et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62, 3408–3416 (2002).
  CAS PubMed Google Scholar
• Gadgeel, S. M., LoRusso, P. M., Wozniak, A. J. & Wheeler, C. A dose-escalation study of the novel vascular–targeting agent, ZD6126, in patients with solid tumors. in Proc. Am. Soc. Clin. Oncol. 24, 438 (2002).
  Google Scholar
• Galbraith, S. M. et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol. 20, 3826–3840 (2002).
  CAS PubMed Google Scholar
• Anderson, H. L. et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 21, 2823–2830 (2003).
  CAS PubMed Google Scholar
• Galbraith, S. M. et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 21, 2831–2842 (2003). Report of the magnetic-resonance-imaging studies in the UK-based Phase I and II clinical trial of CA-4-P. This report shows that the pattern of vascular effects observed in humans is very similar to that predicted from animal studies.
  CAS PubMed Google Scholar
• Stevenson, J. P. et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 21, 4428–4438 (2003).
  CAS PubMed Google Scholar
• Tolcher, A. W. et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days. in Proc. Am. Soc. Clin. Oncol. 22, 834 (2003).
  Google Scholar
• Evelhoch, J. L. et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin. Cancer Res. 10, 3650–3657 (2004).
  CAS PubMed Google Scholar
• Young, S. L. & Chaplin, D. J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin. Investig. Drugs 13, 1171–1182 (2004).
  CAS PubMed Google Scholar
• Steel, G. G. & Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5, 85–91 (1979).
  CAS PubMed Google Scholar
• Siemann, D. W. Vascular targeting agents. Horizons in Cancer Therapeutics: from Bench to Bedside 3, 4–15 (2002).
  Google Scholar
• Cooney, M. M. et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin. Cancer Res. 10, 96–100 (2004).
  CAS PubMed Google Scholar
• Rustin, G. J. et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br. J. Cancer 88, 1160–1167 (2003).
  CAS PubMed PubMed Central Google Scholar
• Li, L., Rojiani, A. & Siemann, D. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 42, 899–903 (1998).
  CAS PubMed Google Scholar
• Wilson, W. R., Li, A. E., Cowan, D. S. & Siim, B. G. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int. J. Radiat. Oncol. Biol. Phys. 42, 905–908 (1998).
  CAS PubMed Google Scholar
• Horsman, M. R. et al. Combretastatins: novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv. Exp. Med. Biol. 476, 311–323 (2000).
  CAS PubMed Google Scholar
• Landuyt, W. et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int. J. Radiat. Oncol. Biol. Phys. 49, 443–450 (2001).
  CAS PubMed Google Scholar
• Murata, R., Siemann, D. W., Overgaard, J. & Horsman, M. R. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat. Res. 156, 503–509 (2001).
  CAS PubMed Google Scholar
• Murata, R., Siemann, D. W., Overgaard, J. & Horsman, H. R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother. Oncol. 60, 155–161 (2001).
  CAS PubMed Google Scholar
• Siemann, D. W. & Rojiani, A. M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 53, 164–171 (2002).
  CAS PubMed Google Scholar
• Siemann, D. W., Mercer, E., Lepler, S. & Rojiani, A. M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer 99, 1–6 (2002).
  CAS PubMed Google Scholar
• Bilenker, J. H. et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin. Cancer Res. 11, 1527–1533 (2005).
  CAS PubMed Google Scholar
• Jain, R. K. Delivery of molecular medicine to solid tumors. Science 271, 1079–1080 (1996).
  CAS PubMed Google Scholar
• Pedley, R. B. et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 59, 3998–4003 (1999).
  CAS PubMed Google Scholar
• Pedley, R. B. et al. Synergy between vascular targeting agents and antibody-directed therapy. Int. J. Radiat. Oncol. Biol. Phys. 54, 1524–1531 (2002).
  CAS PubMed Google Scholar
• Grosios, K., Loadman, P. M., Swaine, D. J., Pettit, G. R. & Bibby, M. C. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 20, 229–234 (2000).
  CAS PubMed Google Scholar
• Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155–1159 (2003).
  CAS PubMed Google Scholar
• Wachsberger, P., Burd, R. & Dicker, A. P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9, 1957–1971 (2003).
  CAS PubMed Google Scholar
• Siemann, D. W. & Horsman, M. R. Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert. Rev. Anticancer Ther. 4, 321–327 (2004). An excellent review of the interaction of vascular-targeting agents with radiotherapy and the issues that need to be addressed.
  CAS PubMed Google Scholar
• El-Emir, E. et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur. J. Cancer 41, 799–806 (2005).
  CAS PubMed Google Scholar
• Wachsberger, P. R. et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin. Cancer. Res. 11, 835–842 (2005).
  CAS PubMed Google Scholar
• Boehle, A. S., Sipos, B., Kliche, U., Kalthoff, H. & Dohrmann, P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann. Thorac. Surg. 71, 1657–1665 (2001).
  CAS PubMed Google Scholar
• Siemann, D. W. & Shi, W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 60, 1233–1240 (2004).
  CAS PubMed Google Scholar
• Siim, B. G., Denny, W. A. & Wilson, W. R. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol. Res. 9, 357–369 (1997).
  CAS PubMed Google Scholar
• Theys, J. et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther. 8, 294–297 (2001).
  CAS PubMed Google Scholar
• Kobayashi, H. et al. Expression of α-smooth muscle actin in benign or malignant ovarian tumors. Gyn. Oncol. 48, 308–313 (1993).
  CAS Google Scholar
• Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363–1380 (2000).
  CAS PubMed PubMed Central Google Scholar
• Paku, S. & Paweletz, N. First steps of tumor-related angiogenesis. Lab. Invest. 65, 334–346 (1991).
  CAS PubMed Google Scholar
• Baluk, P., Morikawa, S., Haskell, A., Mancuso, M. & McDonald, D. M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163, 1801–1815 (2003).
  PubMed PubMed Central Google Scholar
• Jain, R. K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6, 559–593 (1987).
  CAS PubMed Google Scholar
• Dvorak, H. F., Nagy, J. A. & Dvorak, A. M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3, 77–85 (1991).
  CAS PubMed Google Scholar
• Boucher, Y., Baxter, L. T. & Jain, R. K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50, 4478–4484 (1990).
  CAS PubMed Google Scholar
• Jain, R. K. & Ward-Hartley, K. Tumor blood flow- characterization, modifications and role in hyperthermia. IEEE Trans. on sonics & ultrasonics SU-31, 504–526 (1984).
  Google Scholar
• Gillies, R. J., Schornack, P. A., Secomb, T. W. & Raghunand, N. Causes and effects of heterogenous perfusion in tumors. Neoplasia 1, 197–207 (1999).
  CAS PubMed PubMed Central Google Scholar
• Konerding, M. A. et al. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br. J. Cancer 80, 724–732 (1999).
  CAS PubMed PubMed Central Google Scholar
• Sevick, E. M. & Jain, R. K. Geometric resistance to blood flow in solid tumors ex vivo: effects of tumor size and perfusion pressure. Cancer Res. 49, 3506–3512 (1989).
  CAS PubMed Google Scholar
• Lominadze, D. & Mchedlishvili, G. Red blood cell behaviour at low flow rate in microvessels. Microvasc. Res. 58, 187–189 (1999).
  CAS PubMed Google Scholar
• Tozer, G. M., Lewis, S., Michalowski, A. & Aber, V. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br. J. Cancer 61, 250–257 (1990).
  CAS PubMed PubMed Central Google Scholar
• Mueller-Klieser, W., Vaupel, P. & Manz, R. Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int. J. Radiat. Oncol. Biol. Phys. 7, 1397–1404 (1981).
  CAS PubMed Google Scholar
• Vaupel, P. & Hockel, M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int. J. Oncol. 17, 869–879 (2000).
  CAS PubMed Google Scholar
• Jain, R. K. & Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48, 7022–7032 (1988). An excellent analysis of the role of interstitial pressure in the delivery of macromolecules to tumour tissue.
  CAS PubMed Google Scholar